Closed Loop Neuromodulation
Closed-Loop Brain Neuromodulation
Exploring a new way of treating epilepsy
Current Challenges of
Treating Drug-Resistant Epilepsy
Drug-resistant epilepsy (DRE) is a condition in which patients do not respond to available medications and experience recurrent seizures. DRE affects a significant portion of the global population with at least 30% of epilepsy patients experiencing this condition. Unfortunately, available treatment options such as surgery or medication adjustments may not effectively manage DRE patients, and pose side effects or risks.
Although there is a promising solution for DRE known as neuromodulation, there are still several drawbacks that need to be addressed, including limited efficacy, imprecise stimulation, and non-personalized treatment.
Our Solution
INOPASE offers a cutting-edge closed-loop stimulation technology for DRE, with a vision to improve current neuromodulation drawbacks. Our innovative solution offers several advantages, including:
-
Pre-symptomatic detection: Timely stimulation to prevent symptoms before they occur, tailored to each patient for optimal treatment.
-
Personalized treatment: Stimulation adaptable to individual condition, ensuring that each patient receives the most effective treatment possible.
-
Broad, high-density EEG recordings: We offer 64-128 implantable electrodes with thinner and more flexible material, to identify the precise epileptic onset zone.
-
Precise Stimulation: By using broad and high-density electrodes, doctors can locate the optimal brain site for precise stimulation, improving treatment outcomes.
Together, these features make our solution a highly promising and innovative approach to managing DRE, with the potential to significantly improve patients' lives.